礼邦医药(09637.HK)AP301胶囊相关新药上市申请获受理

阿斯达克财经

08/07

礼邦医药-B(09637.HK) 公布，其管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日(7日)获国家药监局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验RESPOND-1的结果及其他累积临床资料。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2657614343"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2657614343\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2657614343?lang=zh_CN&edition=fundamental","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260618090434961_s.png","is_english":false,"pubTime":"2026-08-07 17:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2657614343","market":"fut","top_or_hot":-1,"title":"礼邦医药(09637.HK)AP301胶囊相关新药上市申请获受理","media":"阿斯达克财经","content":"<div>\n<p>礼邦医药-B(09637.HK) 公布，其管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日(7日)获国家药监局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验RESPOND-1的结果及其他累积临床资料。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1537199/latest-news/AAFN\">网页链接</a>\n\n</div>\n","source":"aastocks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>礼邦医药(09637.HK)AP301胶囊相关新药上市申请获受理</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n礼邦医药(09637.HK)AP301胶囊相关新药上市申请获受理\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-07 17:44 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1537199/latest-news/AAFN><strong>阿斯达克财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>礼邦医药-B(09637.HK) 公布，其管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日(7日)获国家药监局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验RESPOND-1的结果及其他累积临床资料。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻</p>\n\n<a href=\"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1537199/latest-news/AAFN\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1537199/latest-news/AAFN","article_id":"2657614343","we_media_id":null,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260618090434961_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1537199/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2657614343","pubTimestamp":1786095840,"columns":[],"sourceInfo":{"source_id":"aastocks_highlight","name":"阿思達克財經"},"weMediaInfo":null,"summary":"礼邦医药-B(09637.HK) 公布，其管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日(7日)获国家药监局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验RESPOND-1的结果及其他累积临床资料。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","BK1191":"制药","BK1161":"生物科技","09939":"开拓药业-B","BK1515":"抗疫概念","BK1574":"生物医药B类股","09637":"礼邦医药-B"},"translate_title":"Li Bang Pharma (09637.HK) AP301 capsule related new drug listing application was accepted","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1.5,"09637":1.5,"09939":1.5},"content_text":"礼邦医药-B(09637.HK) 公布，其管线AP301胶囊(一款新型口服含铁磷结合剂)用于治疗接受维持性透析的慢性肾脏病患者高磷血症的新药上市申请，今日(7日)获国家药监局正式受理。该新药上市申请主要基于AP301在中国完成的关键III期临床试验RESPOND-1的结果及其他累积临床资料。(ha/da)(港股报价延迟最少十五分钟。)AASTOCKS新闻","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}